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Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is the 
second cause of death due to malignancy in the world. The treatment of HCC is complex and 
includes potentially curative and palliative approaches. However, both curative and palliative 
treatments for HCC are often associated with a not-completely favorable safety/efficacy ratio. 
Therefore, other treatment options appear necessary in clinical practice. Transarterial radioem-
bolization has shown a promising efficacy in terms of disease control and is associated with a 
good safety profile. This review discusses the use of transarterial radioembolization in HCC, 
with a focus on the clinical aspects of this therapeutic strategy.
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Introduction
Hepatocellular carcinoma (HCC) remains a frequent and highly lethal type of cancer.1,2 
According to the most recent data, the global incidence of HCC is still increasing, 
although it varies throughout the world; in 2013, 818,000 global deaths were caused 
by liver cancer, 9% more than that in 2010 (752,000 global deaths).3,4 The treatment 
for HCC is difficult and requires a multidisciplinary approach, whereby specialists in 
gastroenterology, hepatology, radiology, oncology, surgery, and others need to bring 
their expertise to provide patients with the best and most updated therapies.5 Trans-
plantation and surgical removal of liver tumors represent the first-line therapy for HCC. 
Unfortunately, only 20%–30% of patients with HCC are good candidates for resection 
due to either multifocal unresectable tumors or their underlying chronic liver disease.6 
Tumor ablation (such as injection of alcohol, acetic acid, microwaves, laser, cryoabla-
tion, and the most commonly used radiofrequency) has become a frequently used and 
extremely effective nonsurgical treatment that provides excellent local tumor control 
and favorable survival benefit7; however, its use in larger tumors has been unsuccessful.
Transarterial chemoembolization (TACE) is the treatment of choice in larger and later 
staged tumors. TACE consists of intra-arterial infusion of a Lipiodol and a chemothera-
peutic agent such as doxorubicin, followed by an injection of embolic material such as 
gelatin sponge particles or other agents.8 However, the association with some contraindica-
tions makes it difficult to draw any firm conclusion about the tolerability of this treatment 
approach.9 Therefore, other treatment options appear necessary in clinical practice.
Transarterial radioembolization (TARE) has shown a promising efficacy in terms 
of disease control and is associated with a good safety profile. This review discusses 
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the use of TARE in HCC, with a focus on the clinical aspects 
of this therapeutic strategy.
TARE: an overview of basic 
principles
TARE consists of the selective intra-arterial administration 
of microspheres loaded with a radioactive compound such as 
yttrium-90 or Lipiodol labeled with iodine131 or rhenium188 
by means of a percutaneous access. Of note, TARE does not 
exert any macro-embolic effect; therefore, all the effects of 
the treatment depend solely on the radiation carried by the 
microspheres. Overall, a bulk of evidence supports the use 
of this technique in the treatment of primary and metastatic 
HCC and cholangiocarcinoma.10–19
Two different types of microspheres are currently avail-
able: the glass-made TheraSphere® and the resin-made Sir-
Spheres®. Although they differ in a number of characteristics, 
including size and number of injected microspheres, current 
evidence shows the substantial clinical efficacy of the two 
approaches.10–13 However, TheraSphere® has a low embolic 
power, with higher activity for each microsphere (2,500 Bq 
vs 50 Bq for Sir-Spheres®). Therefore, TheraSpehere® is 
more suitable when the prevention of vascular stasis and 
reflux is crucial, while it may not be the ideal choice for the 
treatment of large lesions. On the other hand, Sir-Spheres® 
is characterized by a higher embolic power, thus making it 
suitable in cases of large lesions; however, slow injections 
and angiographic control are necessary with this approach.
From a technical point of view, radioembolization com-
prises several stages.20–23 The first stage is the identification, 
according to a multidisciplinary assessment, of potentially 
eligible patients. Then, a diagnostic angiography is performed 
in order to evaluate the vascular anatomy and establish the 
most appropriate site of access. At the same time, labeled 
macroaggregates of albumin (MAA) are injected; their dif-
fusion is similar to that of radioembolization microspheres 
and therefore can be studied by means of single-photon 
emission computed tomography/computed tomography to 
predict the actual diffusion of TARE microspheres. Of note, 
this simulation of diffusion allows a prediction of response to 
TARE11 and therefore plays a crucial role in the selection of 
patients and in the personalization of treatment. The amount 
of yttrium-90 administered is then specifically calculated for 
each patient in order to achieve the desired activity.12,23–25 The 
use of dual-tracer 99m Tc-MAA-99m Tc-SC fusion single-
photon emission computed tomography, an imaging tool that 
merges data on radioactivity distribution with physiologic 
liver mapping, further enhances tailoring of treatment.26 
Finally, microspheres are injected by a catheter within four 
weeks since the first visit.
However, TARE is not without its complications.27–36 
Adverse events can be either due to delivery of toxic effects 
to nontumor tissues or by problems during the placement 
and manipulation of the catheter. Reported complications 
include liver failure or radio-induced liver disease (incidence 
up to 4%), biliary problems (<10%), post-radioembolization 
syndrome (20%–55%), gastrointestinal problems (<5%), and 
radio-induced pneumonia (<1%). An appropriate selection 
of patients may exclude those at higher risk of reporting 
TARE-associated adverse events. Moreover, medical treat-
ment with proton pump inhibitors, steroids, analgesics, and 
anti-emetics can prevent the onset or reduce the severity of 
the abovementioned symptoms.
TARE in HCC: current clinical 
evidence
The European Society of Medical Oncology defined TARE 
as a promising and suitable therapeutic option either as a 
“bridging” treatment or as the main therapy for patients 
who present diffuse intrahepatic tumor spread.37 In addition, 
the National Comprehensive Cancer Network recommends 
TARE for patients with unresectable disease due to inad-
equate hepatic reserve, poor performance status, comorbidi-
ties, or specific location and extension of the tumor.38 The 
National Cancer Institute states that this approach may be 
considered in selected patients with liver-confined HCC, who 
are not eligible for transplant or resection.39
However, given its relatively recent introduction in clinical 
practice and the paucity of randomized phase III trials, more 
evidence on the use of TARE needs to be collected for a full 
evaluation of its benefits and risks. The use of TARE in differ-
ent clinical situations is discussed in the following sections.
Early-stage HCC
Liver transplant remains the elective approach for patients 
with early-stage (according to the Barcelona Clinic Liver 
Cancer [BCLC]-A classification) HCC. However, given the 
paucity of donors, patients often experience disease pro-
gression while on the waiting list, and therefore “bridging 
therapies” are often used to delay progression. TARE has 
been recently proposed in this setting,40 but to date specific 
evidence remains scant, and procedural costs are high.
Intermediate-stage HCC
Patients classified as having intermediate-stage (BCLC-B) 
HCC present very heterogeneous characteristics.41,42 The 
Journal of Hepatocellular Carcinoma 2016:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
27
Transarterial radioembolization for hepatocellular carcinoma
elective treatment is TACE, but its use is often not feasible 
due to several contraindications.
TARE may represent a suitable approach in this setting, 
thanks to its overall favorable safety profile. Although no 
head-to-head prospective study versus TACE is available, the 
use of TARE has been investigated in a number of retrospec-
tive studies. TARE is more expensive than TACE; however, 
this latter technique requires multiple procedures and is more 
often associated with adverse events, therefore increasing 
the overall expense.
In a study comparing 123 patients assigned to TARE and 
122 receiving TACE, the former approach was associated 
with longer time to progression (13.3 months vs 8.4 months; 
P=0.046) and less incidence of complications; however, no dif-
ference in overall survival (OS) was reported.43 These findings 
are in line with those reported in other studies.44–46 In a recent 
study, TARE was also associated with a lower need of hos-
pitalization, when compared with TACE.47 Moreover, TARE 
showed a similar efficacy – in terms of survival – as sorafenib, 
which is the only medical treatment currently available for 
HCC and is also effective in patients with BCLC-B disease.48
In selected subjects with intermediate-stage HCC, tumor 
shrinkage is sometimes feasible in order to reduce disease 
burden and allow resectability or transplantation.49 In a ret-
rospective study, TARE and TACE were compared in terms 
of percentage of tumor shrinkage, with TARE showing the 
better outcomes (–58% vs –31%; P=0.023).50
We feel that the possibility of effective tumor downsizing 
in selected patients widens the opportunities for the use of 
TARE. In addition, this technique can be suitable for patients 
with large extent of disease and modest residual liver volume. 
In this subpopulation of BCLC-B patients, TARE can induce 
hypotrophy of the treated hepatic lobe, and therefore hyper-
trophy of the contralateral lobe thus allowing surgery.51,52
Advanced-stage HCC
Sorafenib represents the elective treatment for patients affected 
from advanced-stage (BCLC-C) disease.53–56 In this setting, 
TARE has been associated with an OS of 6–10 months,16,17 
lower than the results reported with sorafenib in clinical 
practice suggesting that TARE may be used in the treatment 
of patients who do not respond or are contraindicated to 
sorafenib treatment. In a recent small Spanish observational 
study on patients with HCC and portal vein invasion, treat-
ment with TARE may be associated with a more prolonged 
survival compared with sorafenib.57 However, other studies 
are necessary to better elucidate the potential alternative role 
of TARE in the treatment of BCLC-C HCC.
According to the preliminary results of the European 
randomized SORAMIC trial, TARE followed by sorafenib 
appears as well tolerated as sorafenib alone.58 In more detail, 
the number of total (196 vs 222) and grade ≥3 (43 vs 47) 
adverse events was similar in combination treatment and 
control arms, respectively. Moreover, the spectrum of adverse 
events was similar in the two groups.
Selection of patients does play a role also in the use of 
TARE for BCLC-C HCC. It has been shown that patients with 
portal vein thrombosis involving segmental or lobar branches 
treated with TARE achieve an OS of up to 23.2 months.59,60 
On the other hand, patients with portal vein thrombosis of the 
common portal trunk or with distant metastases achieve much 
poorer outcomes, with OS often shorter than 6 months.19,61
Conclusion and perspectives
According to available evidence, TARE represents a feasible 
and promising therapy for the treatment of all stages of HCC. 
However, given the relative paucity of evidence on the use 
of TARE in HCC, the conduction of clinical trials on this 
approach will be of utmost importance in the upcoming years.
To this end, the proper evaluation of clinical outcomes 
associated with TARE becomes crucial. At present, the efficacy 
of this technique is usually assessed by measuring changes 
in tumor markers or by radiological findings.62,63 However, 
tumor markers are often not specific and may fail in provid-
ing well-grounded clinical indications.64 The use of adequate 
evaluation criteria, such as the mRECIST criteria, can enhance 
accuracy.65,66 Of note, tumor necrosis determined by TARE is 
often irregular in distribution and contrast enhancement; there-
fore, the use of volumetric measurements of tumor necrosis 
has been proposed for the early identification of responders.67,68 
These evaluation approaches will allow a more comprehensive 
evaluation of TARE pros and cons in the upcoming years.
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